Podcast Roy S. Herbst, MD @DrRoyHerbstYale @YaleCancer #NSCLC #COAST Phase II COAST Study

Podcast Roy S. Herbst, MD @DrRoyHerbstYale @YaleCancer #N...

Cancer News Photo
Cancer News
4 mesi
21 Visualizzazioni
Vuoi vederlo di nuovo più tardi?
Accedi per aggiungere questo video a una playlist. Accedi
0 0
Categoria:
Descrizione:

Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.

 

Summary:

 

COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with new medicines in individuals with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC).